Find Experts

Experts in Haematology
Julio A Aguirre-Ghiso Alberto Toso Yan Xiaojing William G. Finn Afua Mensah Scott A. Armstrong Richard Oscar Francis Jose Javier Bravo Cordero Steven J Burakoff Arek Z. Dudek Balkrishna Jahagirdar Dan J. Schneider Dr. David Saunders Bamlaku Enawgaw Dylan Zylla Muhammad Yasin Tipu Mr. Máté SZILASSY Mr. Roberto MARCOS Mr. Brian CONIBERE Mr. Julio FREYRE View More
Michael W. Deininger

Professor
Department of Internal Medicine
Huntsman Cancer Institute
United States of America

Professor Haematology
Biography

Michael Deininger, MD, PhD, is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He has extensive experience treating patients with blood cancers. He has a particular interest in chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia. He sees patients at the University of Utah Huntsman Cancer Institute, Clinic 2C.

Research Intrest

Chronic Myeloid Leukemia Myeloproliferative Neoplasms Leukemia Drug Resistance

List of Publications
Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S (2016). A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.LID - haematol.2016.148924 [pii]. (Epub ahead of print) Haematologica.
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H (2016). Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(12), 1572-1611.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, OBrien SG, Druker BJ (2017). Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med, 376(10), 917-927.
Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H (2017). Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol, 10(1), 55.
Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A (2017). Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Rep, 18(13), 3204-3218.
Experts in United States of America
Jairaj K. Acharya John Belote Wayde Brown Aimée M. Dudley Jon P Mochel Rabaa M. Al-Rousan Chancellor, Renate Karen Lee Abt Lin Li Hui-Hsien Chou Hamed I. Aly Cory K. Adams Mark Ehrensberger Jose Buitrago Gerhard J. Barone Jacquelyne Adams Jon Calabria Shelley Cannady Susan B. Adams Stoica George Daniel E. Acuna Tal Amasay Jason R. Wiles Matthew H Andersen Brian Rothman View More